Related Experiment Video

Updated: Mar 14, 2026

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice
08:55

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice

Published on: July 4, 2018

8.3K

RNF5, DAB2 and Friends: Novel Drug Targets for Cystic Fibrosis

Elvira Sondo, Emanuela Pesce, Valeria Tomati

  • 1U.O.C. Genetica Medica, Istituto Giannina Gaslini, Genova, Italy.

Current Pharmaceutical Design
|October 11, 2016
PubMed
Abstract

Insights

Cystic fibrosis drug development requires understanding F508del-CFTR protein defects. Combinations of correctors targeting different mechanisms are crucial for effective cystic fibrosis (CF) therapies.

Area of Science:

  • Molecular Biology
  • Pharmacology
  • Genetics

Background:

  • Cystic fibrosis (CF) is primarily caused by the F508del mutation in the CFTR gene.
  • This mutation leads to protein misfolding, ER retention, reduced channel function, and decreased membrane stability.
  • These defects collectively impair CFTR function in CF patients.

Purpose of the Study:

  • To review the druggability of the F508del-CFTR mutation.
  • To explore novel therapeutic strategies for CF by understanding CFTR processing and degradation.
  • To identify promising pathways and targets for developing new CF pharmacotherapies.

Main Methods:

  • Review of studies demonstrating the druggability of F508del-CFTR.
  • Analysis of corrector molecules that improve CFTR maturation and trafficking.
  • Investigation of pharmacological chaperones and proteostasis regulators as therapeutic approaches.

Main Results:

  • Correctors can act as pharmacological chaperones or proteostasis regulators.
  • Single corrector compounds are insufficient for therapeutically relevant F508del-CFTR rescue.
  • Combination therapy using multiple correctors with distinct mechanisms is necessary for effective CF treatment.

Conclusions:

  • Understanding CFTR processing and degradation is key to developing more effective CF drugs.
  • Combination therapies, such as pairing pharmacological chaperones with proteostasis regulators, show promise.
  • Further research into molecular pathways offers potential for novel CF pharmacotherapies.
Keywords:
CFTRchaperonechloride secretioncorrectordrug therapyproteostasistrafficking

More Related Videos

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

20.2K
Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

11.2K

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
994
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
601
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
61
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
4.6K